{
    "address": "Symbion, Fruebjergvej 3",
    "city": "KOEBENHAVN",
    "country": "DK",
    "currency": "DKK",
    "cusip": "K8553V103",
    "description": "Scandion Oncology A/S engages in the development of drugs for the treatment of cancers that have developed resistance to chemotherapy. The firm was founded in May 2017 and is located in Copenhagen, Denmark. The company focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "N/A",
    "ggroup": "N/A",
    "gind": "N/A",
    "gsector": "N/A",
    "gsubind": "N/A",
    "ipo": "2018-11-08",
    "isin": "DK0061031895",
    "logo": "",
    "marketCapitalization": 537.3053,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Scandion Oncology A/S",
    "phone": "",
    "sedol": "BD9PHW7",
    "shareOutstanding": 32.135544,
    "state": "",
    "ticker": "SCOL.ST",
    "weburl": "https://scandiononcology.com/"
}